Interleukin-37 is increased in adult-onset Still’s disease and associated with disease activity
Interleukin (IL)-37 has been known to play an immunosuppressive role in various inflammatory disorders, but whether it participates in the regulation of pathogenesis of adult-onset Still's disease (AOSD) has not been investigated. In this study, we examined serum IL-37 levels and their clinical...
Saved in:
Published in | Arthritis research & therapy Vol. 20; no. 1; pp. 54 - 12 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
22.03.2018
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Interleukin (IL)-37 has been known to play an immunosuppressive role in various inflammatory disorders, but whether it participates in the regulation of pathogenesis of adult-onset Still's disease (AOSD) has not been investigated. In this study, we examined serum IL-37 levels and their clinical association with AOSD, and we explored the anti-inflammatory effects of IL-37 on peripheral blood mononuclear cells (PBMCs) from patients with AOSD.
Blood samples were collected from 62 patients with AOSD and 50 healthy control subjects (HC). The serum IL-37 levels were determined using an enzyme-linked immunosorbent assay (ELISA). The correlations of serum IL-37 levels with disease activity, laboratory values, and inflammatory cytokines in AOSD were analyzed by Spearman's correlation test. The correlations between serum IL-37 levels and clinical manifestations were analyzed by Mann-Whitney U test. PBMCs from ten patients with AOSD were stimulated with recombinant human IL-37 protein, and expression levels of tumor necrosis factor (TNF)-α, IL-6, IL-10, IL-1β, and IL-18 were determined by qRT-PCR and ELISA.
A significantly higher IL-37 protein level was observed in patients with AOSD than in HC. Serum IL-37 levels correlated with systemic score, laboratory values, IL-1β, IL-18, and IL-10 in patients with AOSD. The expression levels of IL-37 were closely related to the patients with AOSD who also had fever, skin rash, lymphadenopathy, splenomegaly, myalgia, and arthralgia. Moreover, the production of proinflammatory cytokines such as IL-6, IL-1β, TNF-α, and IL-18 in PBMCs from patients with AOSD was obviously attenuated after recombinant human IL-37 stimulation.
Increased expression of IL-37 and its positive correlation with disease activity suggest its involvement in AOSD pathogenesis. More importantly, IL-37 inhibits the expression of proinflammatory cytokines in PBMCs from patients with AOSD, indicating the potential anti-inflammatory role of IL-37 in AOSD. Thus, IL-37 may be a novel disease activity biomarker and research target in AOSD. |
---|---|
AbstractList | Abstract Background Interleukin (IL)-37 has been known to play an immunosuppressive role in various inflammatory disorders, but whether it participates in the regulation of pathogenesis of adult-onset Still’s disease (AOSD) has not been investigated. In this study, we examined serum IL-37 levels and their clinical association with AOSD, and we explored the anti-inflammatory effects of IL-37 on peripheral blood mononuclear cells (PBMCs) from patients with AOSD. Methods Blood samples were collected from 62 patients with AOSD and 50 healthy control subjects (HC). The serum IL-37 levels were determined using an enzyme-linked immunosorbent assay (ELISA). The correlations of serum IL-37 levels with disease activity, laboratory values, and inflammatory cytokines in AOSD were analyzed by Spearman’s correlation test. The correlations between serum IL-37 levels and clinical manifestations were analyzed by Mann-Whitney U test. PBMCs from ten patients with AOSD were stimulated with recombinant human IL-37 protein, and expression levels of tumor necrosis factor (TNF)-α, IL-6, IL-10, IL-1β, and IL-18 were determined by qRT-PCR and ELISA. Results A significantly higher IL-37 protein level was observed in patients with AOSD than in HC. Serum IL-37 levels correlated with systemic score, laboratory values, IL-1β, IL-18, and IL-10 in patients with AOSD. The expression levels of IL-37 were closely related to the patients with AOSD who also had fever, skin rash, lymphadenopathy, splenomegaly, myalgia, and arthralgia. Moreover, the production of proinflammatory cytokines such as IL-6, IL-1β, TNF-α, and IL-18 in PBMCs from patients with AOSD was obviously attenuated after recombinant human IL-37 stimulation. Conclusions Increased expression of IL-37 and its positive correlation with disease activity suggest its involvement in AOSD pathogenesis. More importantly, IL-37 inhibits the expression of proinflammatory cytokines in PBMCs from patients with AOSD, indicating the potential anti-inflammatory role of IL-37 in AOSD. Thus, IL-37 may be a novel disease activity biomarker and research target in AOSD. Interleukin (IL)-37 has been known to play an immunosuppressive role in various inflammatory disorders, but whether it participates in the regulation of pathogenesis of adult-onset Still's disease (AOSD) has not been investigated. In this study, we examined serum IL-37 levels and their clinical association with AOSD, and we explored the anti-inflammatory effects of IL-37 on peripheral blood mononuclear cells (PBMCs) from patients with AOSD.BACKGROUNDInterleukin (IL)-37 has been known to play an immunosuppressive role in various inflammatory disorders, but whether it participates in the regulation of pathogenesis of adult-onset Still's disease (AOSD) has not been investigated. In this study, we examined serum IL-37 levels and their clinical association with AOSD, and we explored the anti-inflammatory effects of IL-37 on peripheral blood mononuclear cells (PBMCs) from patients with AOSD.Blood samples were collected from 62 patients with AOSD and 50 healthy control subjects (HC). The serum IL-37 levels were determined using an enzyme-linked immunosorbent assay (ELISA). The correlations of serum IL-37 levels with disease activity, laboratory values, and inflammatory cytokines in AOSD were analyzed by Spearman's correlation test. The correlations between serum IL-37 levels and clinical manifestations were analyzed by Mann-Whitney U test. PBMCs from ten patients with AOSD were stimulated with recombinant human IL-37 protein, and expression levels of tumor necrosis factor (TNF)-α, IL-6, IL-10, IL-1β, and IL-18 were determined by qRT-PCR and ELISA.METHODSBlood samples were collected from 62 patients with AOSD and 50 healthy control subjects (HC). The serum IL-37 levels were determined using an enzyme-linked immunosorbent assay (ELISA). The correlations of serum IL-37 levels with disease activity, laboratory values, and inflammatory cytokines in AOSD were analyzed by Spearman's correlation test. The correlations between serum IL-37 levels and clinical manifestations were analyzed by Mann-Whitney U test. PBMCs from ten patients with AOSD were stimulated with recombinant human IL-37 protein, and expression levels of tumor necrosis factor (TNF)-α, IL-6, IL-10, IL-1β, and IL-18 were determined by qRT-PCR and ELISA.A significantly higher IL-37 protein level was observed in patients with AOSD than in HC. Serum IL-37 levels correlated with systemic score, laboratory values, IL-1β, IL-18, and IL-10 in patients with AOSD. The expression levels of IL-37 were closely related to the patients with AOSD who also had fever, skin rash, lymphadenopathy, splenomegaly, myalgia, and arthralgia. Moreover, the production of proinflammatory cytokines such as IL-6, IL-1β, TNF-α, and IL-18 in PBMCs from patients with AOSD was obviously attenuated after recombinant human IL-37 stimulation.RESULTSA significantly higher IL-37 protein level was observed in patients with AOSD than in HC. Serum IL-37 levels correlated with systemic score, laboratory values, IL-1β, IL-18, and IL-10 in patients with AOSD. The expression levels of IL-37 were closely related to the patients with AOSD who also had fever, skin rash, lymphadenopathy, splenomegaly, myalgia, and arthralgia. Moreover, the production of proinflammatory cytokines such as IL-6, IL-1β, TNF-α, and IL-18 in PBMCs from patients with AOSD was obviously attenuated after recombinant human IL-37 stimulation.Increased expression of IL-37 and its positive correlation with disease activity suggest its involvement in AOSD pathogenesis. More importantly, IL-37 inhibits the expression of proinflammatory cytokines in PBMCs from patients with AOSD, indicating the potential anti-inflammatory role of IL-37 in AOSD. Thus, IL-37 may be a novel disease activity biomarker and research target in AOSD.CONCLUSIONSIncreased expression of IL-37 and its positive correlation with disease activity suggest its involvement in AOSD pathogenesis. More importantly, IL-37 inhibits the expression of proinflammatory cytokines in PBMCs from patients with AOSD, indicating the potential anti-inflammatory role of IL-37 in AOSD. Thus, IL-37 may be a novel disease activity biomarker and research target in AOSD. Interleukin (IL)-37 has been known to play an immunosuppressive role in various inflammatory disorders, but whether it participates in the regulation of pathogenesis of adult-onset Still's disease (AOSD) has not been investigated. In this study, we examined serum IL-37 levels and their clinical association with AOSD, and we explored the anti-inflammatory effects of IL-37 on peripheral blood mononuclear cells (PBMCs) from patients with AOSD. Blood samples were collected from 62 patients with AOSD and 50 healthy control subjects (HC). The serum IL-37 levels were determined using an enzyme-linked immunosorbent assay (ELISA). The correlations of serum IL-37 levels with disease activity, laboratory values, and inflammatory cytokines in AOSD were analyzed by Spearman's correlation test. The correlations between serum IL-37 levels and clinical manifestations were analyzed by Mann-Whitney U test. PBMCs from ten patients with AOSD were stimulated with recombinant human IL-37 protein, and expression levels of tumor necrosis factor (TNF)-α, IL-6, IL-10, IL-1β, and IL-18 were determined by qRT-PCR and ELISA. A significantly higher IL-37 protein level was observed in patients with AOSD than in HC. Serum IL-37 levels correlated with systemic score, laboratory values, IL-1β, IL-18, and IL-10 in patients with AOSD. The expression levels of IL-37 were closely related to the patients with AOSD who also had fever, skin rash, lymphadenopathy, splenomegaly, myalgia, and arthralgia. Moreover, the production of proinflammatory cytokines such as IL-6, IL-1β, TNF-α, and IL-18 in PBMCs from patients with AOSD was obviously attenuated after recombinant human IL-37 stimulation. Increased expression of IL-37 and its positive correlation with disease activity suggest its involvement in AOSD pathogenesis. More importantly, IL-37 inhibits the expression of proinflammatory cytokines in PBMCs from patients with AOSD, indicating the potential anti-inflammatory role of IL-37 in AOSD. Thus, IL-37 may be a novel disease activity biomarker and research target in AOSD. |
ArticleNumber | 54 |
Audience | Academic |
Author | Wu, Xinyao Sun, Yue Yin, Yufeng Chi, Huihui Shi, Hui Liu, Honglei Cheng, Xiaobing Ye, Junna Liu, Mengru Su, Yutong Zhou, Zhuochao Liu, Dongzhou Yang, Chengde Hu, Qiongyi Teng, Jialin |
Author_xml | – sequence: 1 givenname: Huihui surname: Chi fullname: Chi, Huihui – sequence: 2 givenname: Dongzhou surname: Liu fullname: Liu, Dongzhou – sequence: 3 givenname: Yue surname: Sun fullname: Sun, Yue – sequence: 4 givenname: Qiongyi surname: Hu fullname: Hu, Qiongyi – sequence: 5 givenname: Honglei surname: Liu fullname: Liu, Honglei – sequence: 6 givenname: Xiaobing surname: Cheng fullname: Cheng, Xiaobing – sequence: 7 givenname: Junna surname: Ye fullname: Ye, Junna – sequence: 8 givenname: Hui surname: Shi fullname: Shi, Hui – sequence: 9 givenname: Yufeng surname: Yin fullname: Yin, Yufeng – sequence: 10 givenname: Mengru surname: Liu fullname: Liu, Mengru – sequence: 11 givenname: Xinyao surname: Wu fullname: Wu, Xinyao – sequence: 12 givenname: Zhuochao surname: Zhou fullname: Zhou, Zhuochao – sequence: 13 givenname: Jialin surname: Teng fullname: Teng, Jialin – sequence: 14 givenname: Chengde surname: Yang fullname: Yang, Chengde – sequence: 15 givenname: Yutong surname: Su fullname: Su, Yutong |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29566725$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kstu1TAQhiNURC_wAGxQJDZsUnyJL2eDVFUUjlSJBbC2Js7k1MXHLrFT1B2v0dfjSXBIKT0IIUv2aOb7f43tOaz2QgxYVc8pOaZUy9eJcqJEQ6huqBCikY-qA9oq3Ugu2d6DeL86TOmSEMZWrH1S7bOVkFIxcVDBOmQcPU5fXGi4ql2qXbAjQsK-RDX0k89NDAlz_TE77398v01179JM1BD6GlKK1kEu_DeXL_7UbHbXLt88rR4P4BM-uzuPqs9nbz-dvm_OP7xbn56cN1ZwlhsKCnqNEi0I1kkr5w04qqEdpLUSNbaCMo1ECM16q4ATpjkbtNKak5YfVevFt49waa5Gt4XxxkRw5lcijhsDY3bWo5FdNwxKrBjRom35oJFxWPFWqV6KDnnxerN4XU3dFnuLIY_gd0x3K8FdmE28NkJLrlaqGLy6Mxjj1wlTNluXLHoPAeOUDCt_RijXVBT05YJuoLTmwhCLo51xcyJayVpO5Gx4_A-qrB63zpaxGFzJ7whePLzCfe-_v74AdAHsGFMacbhHKDHzeJllvExp1czjZWTRqL801mXILs6v4Px_lD8BMjnT_Q |
CitedBy_id | crossref_primary_10_1093_rheumatology_keab485 crossref_primary_10_1080_02770903_2021_1878533 crossref_primary_10_1080_14737159_2019_1615449 crossref_primary_10_3389_fimmu_2021_708425 crossref_primary_10_3389_fimmu_2021_654811 crossref_primary_10_3389_fimmu_2020_603389 crossref_primary_10_1007_s00393_022_01276_4 crossref_primary_10_1016_j_semarthrit_2021_06_004 crossref_primary_10_1093_rheumatology_kead507 crossref_primary_10_1007_s10067_018_4288_7 crossref_primary_10_1016_S2665_9913_24_00225_X crossref_primary_10_1038_s41584_019_0277_8 crossref_primary_10_1007_s00393_022_01294_2 crossref_primary_10_47360_1995_4484_2021_643_663 crossref_primary_10_1080_08820139_2024_2443253 crossref_primary_10_3390_jcm11082232 crossref_primary_10_47360_1995_4484_2022_195_204 crossref_primary_10_1097_MD_0000000000023579 crossref_primary_10_1186_s12967_018_1655_8 crossref_primary_10_1007_s10067_020_05094_4 crossref_primary_10_3389_fmed_2020_566738 crossref_primary_10_1186_s43166_021_00065_2 crossref_primary_10_1080_17520363_2024_2403330 crossref_primary_10_3389_fmed_2022_881431 crossref_primary_10_3390_ijms232112810 crossref_primary_10_1097_CM9_0000000000000538 crossref_primary_10_3389_fmed_2019_00266 crossref_primary_10_3389_fimmu_2020_02112 crossref_primary_10_1007_s10067_019_04642_x crossref_primary_10_1016_j_cytogfr_2019_10_003 crossref_primary_10_1155_2021_6650928 crossref_primary_10_3390_jcm10050910 crossref_primary_10_3390_ijms24010372 crossref_primary_10_1080_1744666X_2018_1533403 |
Cites_doi | 10.1371/journal.ppat.1004462 10.1016/j.autrev.2014.08.032 10.3109/03009742.2014.992949 10.1186/s12967-015-0394-3 10.1093/rheumatology/keq133 10.1155/2012/317820 10.1093/rheumatology/kew325 10.1093/rheumatology/kew300 10.1007/s10067-013-2381-5 10.1093/rheumatology/keq284 10.1155/2012/156890 10.1016/j.berh.2008.08.006 10.3389/fphar.2017.00369 10.1093/rheumatology/ket250 10.1073/pnas.1619667114 10.1684/ecn.2011.0288 10.1016/j.cyto.2015.06.005 10.1089/bio.2015.0104 10.1093/rheumatology/40.12.1398 10.1016/j.semarthrit.2012.03.004 10.1111/cei.12061 10.1210/en.2016-1167 10.1155/2012/964751 10.4049/jimmunol.1401810 10.1111/imr.12605 10.1038/ni.1944 10.1038/nrrheum.2011.68 10.1002/art.1780300209 10.1038/sj.gene.6363922 10.1002/acr.22194 10.1097/00005792-199103000-00004 10.1016/j.cyto.2014.11.025 10.1186/1479-5876-12-69 10.1016/j.berh.2016.08.003 10.1073/pnas.1416714111 10.1155/2012/879020 10.1002/1529-0131(200107)44:7<1716::AID-ART298>3.0.CO;2-I 10.1136/ard.2003.013680 10.1016/j.autrev.2017.07.017 10.1111/1346-8138.13888 10.1136/ard.47.9.764 10.1073/pnas.1619011114 10.1097/MD.0000000000001554 10.1073/pnas.1523212113 10.1002/art.22981 10.1371/journal.pone.0107183 10.1016/j.cyto.2012.11.025 10.1016/0140-6736(93)91184-N 10.3899/jrheum.100247 10.3109/s10165-008-0065-9 10.3109/07853890.2014.971052 10.1016/j.autrev.2014.01.058 10.1002/1529-0131(200103)44:3<550::AID-ANR103>3.0.CO;2-5 10.1586/17476348.2015.1109452 10.1371/journal.pone.0095346 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2018 BioMed Central Ltd. The Author(s). 2018 |
Copyright_xml | – notice: COPYRIGHT 2018 BioMed Central Ltd. – notice: The Author(s). 2018 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
DOI | 10.1186/s13075-018-1555-6 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1478-6362 |
EndPage | 12 |
ExternalDocumentID | oai_doaj_org_article_6bbff7592085443f8e23a93477d65be3 PMC5863797 A546243067 29566725 10_1186_s13075_018_1555_6 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: ; grantid: 81671589; 81601400 – fundername: ; grantid: GCQN-2017-B04 – fundername: ; grantid: YG2016QN62 – fundername: ; grantid: 17411965100 – fundername: ; grantid: 16YF1407000 |
GroupedDBID | --- .GJ 0R~ 23N 2WC 4.4 5GY 5VS 6J9 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABUWG ACGFS ACJQM ADBBV ADUKV AEGXH AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIAM AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK E3Z EBD EBLON EJD EMOBN F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE HZ~ INH INR ITC KQ8 M1P O5R O5S O9- PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ ROL RPM RSV SMD SOJ SV3 TR2 U2A UKHRP WOQ -5E -5G -A0 -BR 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF IAO IHR NPM Z7U PMFND 7X8 PJZUB PPXIY 5PM PUEGO |
ID | FETCH-LOGICAL-c532t-1a7ad8e6eca52b6c62b6ca3e7f4f6cc6e8e45128e05582dc7a302832f87883043 |
IEDL.DBID | DOA |
ISSN | 1478-6362 1478-6354 |
IngestDate | Wed Aug 27 01:31:53 EDT 2025 Thu Aug 21 13:28:57 EDT 2025 Mon Jul 21 11:42:07 EDT 2025 Tue Jun 17 21:36:48 EDT 2025 Tue Jun 10 20:22:37 EDT 2025 Wed Feb 19 02:35:56 EST 2025 Thu Apr 24 23:08:36 EDT 2025 Tue Jul 01 04:00:50 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Peripheral blood mononuclear cells IL-37 Adult-onset Still’s disease Cytokines |
Language | English |
License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c532t-1a7ad8e6eca52b6c62b6ca3e7f4f6cc6e8e45128e05582dc7a302832f87883043 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://doaj.org/article/6bbff7592085443f8e23a93477d65be3 |
PMID | 29566725 |
PQID | 2018013815 |
PQPubID | 23479 |
PageCount | 12 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_6bbff7592085443f8e23a93477d65be3 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5863797 proquest_miscellaneous_2018013815 gale_infotracmisc_A546243067 gale_infotracacademiconefile_A546243067 pubmed_primary_29566725 crossref_primary_10_1186_s13075_018_1555_6 crossref_citationtrail_10_1186_s13075_018_1555_6 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2018-03-22 |
PublicationDateYYYYMMDD | 2018-03-22 |
PublicationDate_xml | – month: 03 year: 2018 text: 2018-03-22 day: 22 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Arthritis research & therapy |
PublicationTitleAlternate | Arthritis Res Ther |
PublicationYear | 2018 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | AT Maria (1555_CR8) 2014; 13 C Girard (1555_CR40) 2016; 55 CP Mavragani (1555_CR45) 2012; 2012 G Cavalli (1555_CR29) 2018; 281 T Sugiura (1555_CR9) 2002; 3 H Imaeda (1555_CR51) 2013; 172 M Gerfaud-Valentin (1555_CR3) 2014; 13 T Ito (1555_CR53) 2008; 18 F Ortiz-Sanjuán (1555_CR17) 2015; 94 T Fujii (1555_CR19) 2001; 40 S Colafrancesco (1555_CR13) 2012; 2012 IA Al-Homood (1555_CR43) 2014; 53 J Pouchot (1555_CR7) 1993; 341 B Chen (1555_CR28) 2015; 13 DY Chen (1555_CR49) 2004; 63 L Lunding (1555_CR56) 2015; 9 Y Luo (1555_CR57) 2014; 111 S Moretti (1555_CR58) 2014; 10 S Castañeda (1555_CR1) 2016; 30 M Shimizu (1555_CR47) 2010; 49 G Cavalli (1555_CR22) 2015; 44 T Takeichi (1555_CR60) 2017; 44 A Kontzias (1555_CR16) 2012; 42 C Giampietro (1555_CR14) 2012; 2012 M Kawashima (1555_CR10) 2001; 44 T Hoshino (1555_CR12) 1998; 25 MF Nold (1555_CR31) 2010; 11 M Shimizu (1555_CR48) 2013; 61 JM Wouters (1555_CR6) 1988; 47 J Pouchot (1555_CR38) 1991; 70 HW Grievink (1555_CR41) 2016; 14 L Xia (1555_CR25) 2015; 76 P Efthimiou (1555_CR5) 2012; 2012 PW Zhao (1555_CR30) 2014; 9 G Cavalli (1555_CR27) 2016; 55 JJ Cush (1555_CR46) 1987; 30 Y Li (1555_CR36) 2014; 9 M Rau (1555_CR39) 2010; 37 JH Choi (1555_CR50) 2003; 30 P Cipriani (1555_CR15) 2014; 33 S Colafrancesco (1555_CR23) 2017; 8 L Ye (1555_CR26) 2015; 194 Y Su (1555_CR42) 2016; 157 HM Chen (1555_CR59) 2015; 72 Q Zeng (1555_CR35) 2017; 114 M Coll-Miró (1555_CR33) 2016; 113 DY Chen (1555_CR44) 2010; 49 H Ichida (1555_CR20) 2014; 66 Y Kawaguchi (1555_CR11) 2001; 44 ED Mellins (1555_CR54) 2011; 7 L Ye (1555_CR24) 2014; 12 1555_CR2 G Cavalli (1555_CR34) 2017; 114 J Huang (1555_CR55) 2016; 15 D Boraschi (1555_CR32) 2011; 22 B Fautrel (1555_CR4) 2008; 22 N Fall (1555_CR52) 2007; 56 M Govoni (1555_CR21) 2017; 16 M Yamaguchi (1555_CR37) 1992; 19 DY Chen (1555_CR18) 2004; 31 |
References_xml | – volume: 10 start-page: e1004462 issue: 11 year: 2014 ident: 1555_CR58 publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1004462 – volume: 13 start-page: 1149 issue: 11 year: 2014 ident: 1555_CR8 publication-title: Autoimmun Rev doi: 10.1016/j.autrev.2014.08.032 – volume: 44 start-page: 309 issue: 4 year: 2015 ident: 1555_CR22 publication-title: Scand J Rheumatol doi: 10.3109/03009742.2014.992949 – volume: 13 start-page: 36 year: 2015 ident: 1555_CR28 publication-title: J Transl Med doi: 10.1186/s12967-015-0394-3 – volume: 49 start-page: 1645 issue: 9 year: 2010 ident: 1555_CR47 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/keq133 – volume: 31 start-page: 2189 issue: 11 year: 2004 ident: 1555_CR18 publication-title: J Rheumatol – volume: 25 start-page: 396 issue: 2 year: 1998 ident: 1555_CR12 publication-title: J Rheumatol – volume: 2012 start-page: 317820 year: 2012 ident: 1555_CR14 publication-title: Int J Inflamm doi: 10.1155/2012/317820 – volume: 55 start-page: 2220 issue: 12 year: 2016 ident: 1555_CR27 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/kew325 – volume: 55 start-page: 2237 issue: 12 year: 2016 ident: 1555_CR40 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/kew300 – volume: 33 start-page: 49 issue: 1 year: 2014 ident: 1555_CR15 publication-title: Clin Rheumatol doi: 10.1007/s10067-013-2381-5 – volume: 49 start-page: 2305 issue: 12 year: 2010 ident: 1555_CR44 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/keq284 – volume: 2012 start-page: 156890 year: 2012 ident: 1555_CR13 publication-title: Int J Inflamm doi: 10.1155/2012/156890 – volume: 22 start-page: 773 issue: 5 year: 2008 ident: 1555_CR4 publication-title: Best Pract Res Clin Rheumatol doi: 10.1016/j.berh.2008.08.006 – volume: 8 start-page: 369 year: 2017 ident: 1555_CR23 publication-title: Front Pharmacol doi: 10.3389/fphar.2017.00369 – volume: 53 start-page: 32 issue: 1 year: 2014 ident: 1555_CR43 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/ket250 – volume: 114 start-page: 1631 issue: 7 year: 2017 ident: 1555_CR35 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1619667114 – volume: 22 start-page: 127 issue: 3 year: 2011 ident: 1555_CR32 publication-title: Eur Cytokine Netw doi: 10.1684/ecn.2011.0288 – volume: 76 start-page: 553 issue: 2 year: 2015 ident: 1555_CR25 publication-title: Cytokine doi: 10.1016/j.cyto.2015.06.005 – volume: 14 start-page: 410 issue: 5 year: 2016 ident: 1555_CR41 publication-title: Biopreserv Biobank doi: 10.1089/bio.2015.0104 – volume: 40 start-page: 1398 issue: 12 year: 2001 ident: 1555_CR19 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/40.12.1398 – volume: 42 start-page: 201 issue: 2 year: 2012 ident: 1555_CR16 publication-title: Semin Arthritis Rheum doi: 10.1016/j.semarthrit.2012.03.004 – volume: 19 start-page: 424 issue: 3 year: 1992 ident: 1555_CR37 publication-title: J Rheumatol – volume: 172 start-page: 410 issue: 3 year: 2013 ident: 1555_CR51 publication-title: Clin Exp Immunol doi: 10.1111/cei.12061 – volume: 157 start-page: 4782 issue: 12 year: 2016 ident: 1555_CR42 publication-title: Endocrinology doi: 10.1210/en.2016-1167 – volume: 2012 start-page: 964751 year: 2012 ident: 1555_CR5 publication-title: Int J Inflamm doi: 10.1155/2012/964751 – volume: 194 start-page: 5110 issue: 11 year: 2015 ident: 1555_CR26 publication-title: J Immunol doi: 10.4049/jimmunol.1401810 – volume: 281 start-page: 179 issue: 1 year: 2018 ident: 1555_CR29 publication-title: Immunol Rev doi: 10.1111/imr.12605 – volume: 11 start-page: 1014 issue: 11 year: 2010 ident: 1555_CR31 publication-title: Nat Immunol doi: 10.1038/ni.1944 – volume: 30 start-page: 2422 issue: 11 year: 2003 ident: 1555_CR50 publication-title: J Rheumatol – volume: 7 start-page: 416 issue: 7 year: 2011 ident: 1555_CR54 publication-title: Nat Rev Rheumatol doi: 10.1038/nrrheum.2011.68 – volume: 30 start-page: 186 issue: 2 year: 1987 ident: 1555_CR46 publication-title: Arthritis Rheum doi: 10.1002/art.1780300209 – volume: 15 start-page: gmr.15027616 issue: 2 year: 2016 ident: 1555_CR55 publication-title: Genet Mol Res – volume: 3 start-page: 394 issue: 7 year: 2002 ident: 1555_CR9 publication-title: Genes Immun doi: 10.1038/sj.gene.6363922 – volume: 66 start-page: 642 issue: 4 year: 2014 ident: 1555_CR20 publication-title: Arthritis Care Res doi: 10.1002/acr.22194 – volume: 70 start-page: 118 issue: 2 year: 1991 ident: 1555_CR38 publication-title: Medicine (Baltimore) doi: 10.1097/00005792-199103000-00004 – volume: 72 start-page: 113 issue: 1 year: 2015 ident: 1555_CR59 publication-title: Cytokine doi: 10.1016/j.cyto.2014.11.025 – volume: 12 start-page: 69 year: 2014 ident: 1555_CR24 publication-title: J Transl Med doi: 10.1186/1479-5876-12-69 – volume: 30 start-page: 222 issue: 2 year: 2016 ident: 1555_CR1 publication-title: Best Pract Res Clin Rheumatol doi: 10.1016/j.berh.2016.08.003 – volume: 111 start-page: 15178 issue: 42 year: 2014 ident: 1555_CR57 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1416714111 – volume: 2012 start-page: 879020 year: 2012 ident: 1555_CR45 publication-title: Int J Inflamm doi: 10.1155/2012/879020 – volume: 44 start-page: 1716 issue: 7 year: 2001 ident: 1555_CR11 publication-title: Arthritis Rheum doi: 10.1002/1529-0131(200107)44:7<1716::AID-ART298>3.0.CO;2-I – volume: 63 start-page: 1300 issue: 10 year: 2004 ident: 1555_CR49 publication-title: Ann Rheum Dis doi: 10.1136/ard.2003.013680 – volume: 16 start-page: 1016 issue: 10 year: 2017 ident: 1555_CR21 publication-title: Autoimmun Rev doi: 10.1016/j.autrev.2017.07.017 – volume: 44 start-page: 1172 issue: 10 year: 2017 ident: 1555_CR60 publication-title: J Dermatol doi: 10.1111/1346-8138.13888 – volume: 47 start-page: 764 issue: 9 year: 1988 ident: 1555_CR6 publication-title: Ann Rheum Dis doi: 10.1136/ard.47.9.764 – volume: 114 start-page: 2313 issue: 9 year: 2017 ident: 1555_CR34 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1619011114 – volume: 94 start-page: e1554 issue: 39 year: 2015 ident: 1555_CR17 publication-title: Medicine (Baltimore) doi: 10.1097/MD.0000000000001554 – volume: 113 start-page: 1411 issue: 5 year: 2016 ident: 1555_CR33 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1523212113 – volume: 56 start-page: 3793 issue: 11 year: 2007 ident: 1555_CR52 publication-title: Arthritis Rheum doi: 10.1002/art.22981 – volume: 9 start-page: e107183 issue: 9 year: 2014 ident: 1555_CR36 publication-title: PLoS One doi: 10.1371/journal.pone.0107183 – volume: 61 start-page: 345 issue: 2 year: 2013 ident: 1555_CR48 publication-title: Cytokine doi: 10.1016/j.cyto.2012.11.025 – volume: 341 start-page: 1280 issue: 8855 year: 1993 ident: 1555_CR7 publication-title: Lancet doi: 10.1016/0140-6736(93)91184-N – volume: 37 start-page: 2369 issue: 11 year: 2010 ident: 1555_CR39 publication-title: J Rheumatol doi: 10.3899/jrheum.100247 – volume: 18 start-page: 407 issue: 4 year: 2008 ident: 1555_CR53 publication-title: Mod Rheumatol doi: 10.3109/s10165-008-0065-9 – ident: 1555_CR2 doi: 10.3109/07853890.2014.971052 – volume: 13 start-page: 708 issue: 7 year: 2014 ident: 1555_CR3 publication-title: Autoimmun Rev doi: 10.1016/j.autrev.2014.01.058 – volume: 44 start-page: 550 issue: 3 year: 2001 ident: 1555_CR10 publication-title: Arthritis Rheum doi: 10.1002/1529-0131(200103)44:3<550::AID-ANR103>3.0.CO;2-5 – volume: 9 start-page: 739 issue: 6 year: 2015 ident: 1555_CR56 publication-title: Expert Rev Respir Med doi: 10.1586/17476348.2015.1109452 – volume: 9 start-page: e95346 issue: 5 year: 2014 ident: 1555_CR30 publication-title: PLoS One doi: 10.1371/journal.pone.0095346 |
SSID | ssj0022924 |
Score | 2.4049258 |
Snippet | Interleukin (IL)-37 has been known to play an immunosuppressive role in various inflammatory disorders, but whether it participates in the regulation of... Abstract Background Interleukin (IL)-37 has been known to play an immunosuppressive role in various inflammatory disorders, but whether it participates in the... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 54 |
SubjectTerms | Adult Adult-onset Still’s disease Biomarkers - blood Cells, Cultured Cytokines Disease Progression Female Humans IL-37 Interleukin-1 - blood Interleukins Leukocytes, Mononuclear - metabolism Male Middle Aged Peripheral blood mononuclear cells Physiological aspects Still's Disease, Adult-Onset - blood Still's Disease, Adult-Onset - diagnosis Young Adult |
Title | Interleukin-37 is increased in adult-onset Still’s disease and associated with disease activity |
URI | https://www.ncbi.nlm.nih.gov/pubmed/29566725 https://www.proquest.com/docview/2018013815 https://pubmed.ncbi.nlm.nih.gov/PMC5863797 https://doaj.org/article/6bbff7592085443f8e23a93477d65be3 |
Volume | 20 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1fi9QwEA96gvgi_rd6LhUEQSjX5n8f9-SOQ7hD1IV9C2maYHHpie2--zX8en4SZ9LsukXQF19C6aQwyUwyM8n0N4S8CqyhAQxBUTndFhxMSmHBihV16WiwXDRVrBJxeSUvVvzdWqwPSn1hTtgEDzxN3IlsmhCUqLGWJOcsaE-ZrRlXqpWi8RHnE2zeLphKoRaFsCLdYVZangywUytMUgOehBCFnFmhCNb_55Z8YJPm-ZIHBuj8HrmbPMd8OXF8n9zw_QNy-zLdjT8kNh7ubfz2S9fDgs67Ie969AkH38JTHpE2CkyeHvOPY7fZ_Pz-Y8jTBU1u-za3SVTQH49nf9PcVGLiEVmdn316e1GkAgqFE4yORWWVbbWX3llBG-kkNpZ5FXiQzkmvPUpH-1IITVunLIuli4KGwJiVnD0mR_1175-S3FbU6YpXljnPYXpr8HxqEGdFS181bchIuZtQ4xK6OBa52JgYZWhpJhkYkIFBGRiZkTf7T75O0Bp_63yKUtp3RFTs-AJ0xSRdMf_SlYy8RhkbXLvAnLPpFwQYIqJgmaXgknIMojJyPOsJa87NyC93WmKQhIlqvb_eDoYiIFoFbpDIyJNJa_Y8U4hFpaJAUTN9mg1qTum7zxHyW2jJVK2e_Y9ZeE7uIJeYSEfpMTkav239C_CsxmZBbqq1WpBbp2dX7z8s4pKCdkWXvwAcIiJd |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Interleukin-37+is+increased+in+adult-onset+Still%E2%80%99s+disease+and+associated+with+disease+activity&rft.jtitle=Arthritis+research+%26+therapy&rft.au=Huihui+Chi&rft.au=Dongzhou+Liu&rft.au=Yue+Sun&rft.au=Qiongyi+Hu&rft.date=2018-03-22&rft.pub=BMC&rft.eissn=1478-6362&rft.volume=20&rft.issue=1&rft.spage=1&rft.epage=12&rft_id=info:doi/10.1186%2Fs13075-018-1555-6&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_6bbff7592085443f8e23a93477d65be3 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-6362&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-6362&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-6362&client=summon |